Last reviewed · How we verify
2LHERP®
2LHERP® is a marketed small molecule drug developed by Labo'Life, with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with a specific target in the body, providing a targeted therapeutic approach. The primary risk to 2LHERP® is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | 2LHERP® |
|---|---|
| Also known as | 2LHERP |
| Sponsor | Labo'Life |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections. (PHASE4)
- Study of 2LHERP® in Genital Herpes Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |